Published in Cancer Immunol Immunother on November 01, 2000
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther (2010) 3.29
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J Acquir Immune Defic Syndr (2007) 1.73
Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells. Clin Cancer Res (2009) 1.59
Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev (2009) 1.44
Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest (2005) 1.24
Lung cancer immunotherapy. Clin Med Res (2005) 1.04
The highly attenuated vaccinia virus strain modified virus Ankara induces apoptosis in melanoma cells and allows bystander dendritic cells to generate a potent anti-tumoral immunity. Clin Exp Immunol (2006) 1.04
The evolution of poxvirus vaccines. Viruses (2015) 1.02
Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review. J Transl Med (2011) 0.97
Synergetic anticancer effect of combined quercetin and recombinant adenoviral vector expressing human wild-type p53, GM-CSF and B7-1 genes on hepatocellular carcinoma cells in vitro. World J Gastroenterol (2003) 0.96
Immunotherapy for colorectal cancer. World J Gastroenterol (2013) 0.94
Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugs. J Cancer Res Clin Oncol (2003) 0.91
Immunotherapy for gastrointestinal malignancies. Cancer Control (2013) 0.90
Gene Therapy Applications to Cancer Treatment. J Biomed Biotechnol (2003) 0.90
Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention. Clin Dev Immunol (2012) 0.89
Poxviral vectors for cancer immunotherapy. Expert Opin Biol Ther (2012) 0.88
Impact of the immune system and immunotherapy in colorectal cancer. J Gastrointest Oncol (2015) 0.87
Colorectal cancer immunotherapy. Discov Med (2013) 0.87
Bugs as drugs for cancer. Immunology (2002) 0.86
A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma. J Immunother Cancer (2013) 0.85
Gene therapy for lung neoplasms. Clin Chest Med (2011) 0.84
A novel transgenic mouse model for immunological evaluation of carcinoembryonic antigen-based DNA minigene vaccines. J Clin Invest (2004) 0.83
Expression of costimulatory molecule CD80 in colonic dysplasia in ulcerative colitis: an immunosurveillance mechanism against colorectal cancer? Int J Colorectal Dis (2006) 0.81
Antibody-based immunotherapy for malignant glioma. Semin Oncol (2014) 0.80
A translational approach to lung cancer research: From EGFRs to Wnt and cancer stem cells. Ann Thorac Cardiovasc Surg (2009) 0.78
Taking Gene Therapy into the Clinic. J Biomed Biotechnol (2003) 0.77
Effective inhibition of melanoma tumorigenesis and growth via a new complex vaccine based on NY-ESO-1-alum-polysaccharide-HH2. Mol Cancer (2014) 0.76
Respiratory Homeostasis and Exploitation of the Immune System for Lung Cancer Vaccines. US Oncol (2009) 0.75
DMC1: a meiosis-specific yeast homolog of E. coli recA required for recombination, synaptonemal complex formation, and cell cycle progression. Cell (1992) 10.48
The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery. Immunity (1999) 6.10
Characterization of the products of DNA-directed DNA polymerases in oncogenic RNA viruses. Nature (1970) 5.23
DNA-directed DNA polymerase activity in oncogenic RNA viruses. Nature (1970) 4.81
The RND permease superfamily: an ancient, ubiquitous and diverse family that includes human disease and development proteins. J Mol Microbiol Biotechnol (1999) 4.64
Synthetic DNA-RNA hybrids and RNA-RNA duplexes as templates for the polymerases of the oncogenic RNA viruses. Nature (1970) 3.98
Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma (1984) 3.74
Simultaneous detection of reverse transcriptase and high molecular weight RNA unique to oncogenic RNA viruses. Science (1971) 3.68
Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci U S A (1999) 3.66
alpha-Synuclein gene duplication is present in sporadic Parkinson disease. Neurology (2007) 3.62
Biodegradable block copolymers as injectable drug-delivery systems. Nature (1997) 3.48
Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A (1998) 3.46
The International Caries Detection and Assessment System (ICDAS): an integrated system for measuring dental caries. Community Dent Oral Epidemiol (2007) 3.34
Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res (1992) 2.83
Mutations in a novel gene, VMD2, encoding a protein of unknown properties cause juvenile-onset vitelliform macular dystrophy (Best's disease). Hum Mol Genet (1998) 2.68
A community study of sleep-disordered breathing in middle-aged Chinese men in Hong Kong. Chest (2001) 2.66
Crystal structure of Thermus aquaticus DNA polymerase. Nature (1995) 2.62
Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol (2000) 2.58
The MLL recombinome of acute leukemias in 2013. Leukemia (2013) 2.55
Serum leptin and vascular risk factors in obstructive sleep apnea. Chest (2000) 2.53
The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesis. Cancer Res (2001) 2.51
Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst (1995) 2.47
Biological behavior of human breast carcinoma-associated antigens expressed during cellular proliferation. Cancer Res (1983) 2.46
Definitions of infection for surveillance in long-term care facilities. Am J Infect Control (1991) 2.33
A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res (1999) 2.33
Presence in human breast cancer of RNA homologous to mouse mammary tumour virus RNA. Nature (1972) 2.31
Major pol gene progenitors in the evolution of oncoviruses. Science (1984) 2.28
A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res (2000) 2.28
What is the role of CSF spectrophotometry in the diagnosis of subarachnoid haemorrhage? Ann Clin Biochem (1998) 2.12
Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res (1995) 2.11
Mutations in the VMD2 gene are associated with juvenile-onset vitelliform macular dystrophy (Best disease) and adult vitelliform macular dystrophy but not age-related macular degeneration. Eur J Hum Genet (2000) 2.02
Bone marrow scintigraphy using technetium-99m-antigranulocyte antibody in hematologic disorders. J Nucl Med (1996) 2.01
The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res (2001) 2.01
A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci U S A (1981) 2.00
Accelerated sea-level rise from West Antarctica. Science (2004) 1.99
Circulating nitric oxide is suppressed in obstructive sleep apnea and is reversed by nasal continuous positive airway pressure. Am J Respir Crit Care Med (2000) 1.97
In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst (1997) 1.92
Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology (1999) 1.92
Factors associated with complications and mortality in adult patients hospitalized for infectious cellulitis. Eur J Clin Microbiol Infect Dis (2003) 1.92
A new class of endogenous human retroviral genomes. Science (1985) 1.89
Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res (1986) 1.86
Generation of human monoclonal antibodies reactive with human mammary carcinoma cells. Proc Natl Acad Sci U S A (1980) 1.86
Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules. J Natl Cancer Inst (2000) 1.85
Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res (1986) 1.84
Apical organization in the somatic hyphae of fungi. J Gen Microbiol (1968) 1.84
Effect of the myotonic dystrophy (DM) mutation on mRNA levels of the DM gene. Nat Genet (1993) 1.79
Evidence for translation of viral-specific RNA in cells of a mouse mammary carcinoma. Proc Natl Acad Sci U S A (1972) 1.76
Detection and cloning of human DNA sequences related to the mouse mammary tumor virus genome. Proc Natl Acad Sci U S A (1982) 1.74
Comparison of MR imaging with PET and ictal SPECT in 118 patients with intractable epilepsy. AJNR Am J Neuroradiol (1999) 1.70
A gene therapy approach for treating T-cell-mediated autoimmune diseases. Blood (2001) 1.69
DNA polymerase activities in varions of visna virus, a causative agent of a "slow" neurological disease. Proc Natl Acad Sci U S A (1971) 1.67
Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. J Nucl Med (1999) 1.63
RNA-dependent DNA polymerase activity in virus-like particles isolated from human milk. Nature (1971) 1.63
TNF-alpha, nitric oxide and IFN-gamma are all critical for development of necrosis in the small intestine and early mortality in genetically susceptible mice infected perorally with Toxoplasma gondii. Parasite Immunol (1999) 1.63
Monoclonal antibodies define differential ras gene expression in malignant and benign colonic diseases. Nature (1984) 1.62
Rel/NF-kappaB can trigger the Notch signaling pathway by inducing the expression of Jagged1, a ligand for Notch receptors. EMBO J (1999) 1.61
In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst (1990) 1.61
Intracranial ictal onset zone in nonlesional lateral temporal lobe epilepsy on scalp ictal EEG. Neurology (2003) 1.60
An all-optical quantum gate in a semiconductor quantum dot. Science (2003) 1.60
Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res (1991) 1.60
Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Cancer Inst (1992) 1.59
DNA polymerase activities and nucleic acid components of virions isolated from a spontaneous mammary carcinoma from a rhesus monkey. Proc Natl Acad Sci U S A (1971) 1.57
Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis (2001) 1.57
Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J Clin Oncol (2001) 1.52
Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin Cancer Res (2000) 1.52
Loss of a c-H-ras-1 allele and aggressive human primary breast carcinomas. Cancer Res (1986) 1.52
Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor. Hum Gene Ther (1999) 1.52
[Complications related with cocaine abuse that required hospital admission]. Rev Clin Esp (2008) 1.51
Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res (2001) 1.51
Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer. J Nucl Med (1992) 1.49
Members of the Gq alpha subunit gene family activate phospholipase C beta isozymes. J Biol Chem (1992) 1.48
Management of chronic obstructive pulmonary disease in Asia and Africa. Int J Tuberc Lung Dis (2004) 1.48
A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations. Int J Cancer (1982) 1.47
A new controlled-rate cooling apparatus for freezing hematopoietic cells for storage at -196 degrees C. Cryobiology (1973) 1.45
Cloning and chromosomal mapping of a gene isolated from thymic stromal cells encoding a new mouse type II membrane serine protease, epithin, containing four LDL receptor modules and two CUB domains. Immunogenetics (1999) 1.42
Mechanisms of action of Pseudomonas aeruginosa pyocyanin on human ciliary beat in vitro. Infect Immun (1993) 1.42
Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res (1991) 1.41
In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer. J Nucl Med (1990) 1.41
Exclusive breast-feeding duration is associated with attitudinal, socioeconomic and biocultural determinants in three Latin American countries. J Nutr (1995) 1.40
Increased carcinoembryonic antigen expression in cervical intraepithelial neoplasia grade 3 and in cervical squamous cell carcinoma. Hum Pathol (2000) 1.40
Survival, morbidity, and resource use of infants of 25 weeks' gestational age or less. Am J Obstet Gynecol (2001) 1.39
Isolation of the mouse mammary tumor virus sequences not transmitted as germinal provirus in the C3H and RIII mouse strains. J Virol (1977) 1.39
Clinical infection control in gene therapy: a multidisciplinary conference. Infect Control Hosp Epidemiol (2000) 1.39
Breastfeeding promotion and priority setting in health. Health Policy Plan (1996) 1.38
Expression of laminin receptor in normal and carcinomatous human tissues as defined by a monoclonal antibody. Cancer Res (1985) 1.37
Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res (2001) 1.35
Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues. Cancer Res (1985) 1.35
Expression of ras oncogene p21 in prostate cancer. N Engl J Med (1986) 1.35
Virus-related RNA in human and mouse mammary tumors. J Natl Cancer Inst (1972) 1.34
Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res (1997) 1.34
Monoclonal antibodies to the human laminin receptor recognize structurally distinct sites. Exp Cell Res (1985) 1.32
Relationship in nucleic acid sequences between mouse mammary tumor virus variants. Proc Natl Acad Sci U S A (1975) 1.32
Jack been urease (EC 3.5.1.5). II. The relationship between nickel, enzymatic activity, and the "abnormal" ultraviolet spectrum. The nickel content of jack beans. Can J Biochem (1980) 1.32
Improving protective immunity induced by DNA-based immunization: priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus. J Immunol (2000) 1.32
Monoclonal antibodies of predefined specificity detect activated ras gene expression in human mammary and colon carcinomas. Proc Natl Acad Sci U S A (1984) 1.32
A biochemical approach to the study of the transmission of mouse mammary tumor viruses in mouse strains RIII and C3H. Int J Cancer (1976) 1.30
Thymic selection by a single MHC/peptide ligand produces a semidiverse repertoire of CD4+ T cells. Immunity (1997) 1.30
A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res (1999) 1.28